Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.01 - $83.00
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.39M
Market Cap
$44.77B
Enterprise Value$42.68B
Total Cash (Recent Filing)$4.06B
Total Debt (Recent Filing)$702.60M
Price to Earnings (P/E)52.1
Beta0.83
Next Earnings
Oct 30, 2025EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding587,100,000
10 Day Avg. Volume5,362,029
30 Day Avg. Volume4,394,566
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit9.51
Enterprise Value/Ebitda23.93
Forecast
1Y Price Target
$88.64Price Target Upside16.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Bulls Say, Bears Say
Bulls Say
Conference PresentationsThe EVOQUE presentation at the conference will provide early commercial experience from the US TVT Registry, attracting investor attention.
Financial PerformanceManagement raised full-year EPS guidance to the high end of $2.45-$2.55, indicating a positive adjustment in financial expectations.
Market ExpansionEdwards will be the only TAVR system with asymptomatic approval, potentially leading to market share gains in the future.
Bears Say
Deal UncertaintyThe delayed closing timeline for the JenaValve deal is perceived as a negative, increasing the risk of the deal not proceeding.
Market VolumesDespite some halo effect benefits, there have yet to be material asymptomatic patient volumes in the TAVR market.
Regulatory RisksThe FTC's lawsuit to block the JenaValve deal introduces a risk that the deal may not close, removing a potential future growth opportunity for Edwards Lifesciences.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $64.00 and its highest was $83.00 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $44.77B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 30, 2025 which is in 31 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 24, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.624 by $0.046.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.59.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 587,100,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.624. Following the earnings report the stock price went up 5.541%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$88.64 (16.25% Upside)
$88.64 (16.25% Upside)
Blogger Sentiment
Bullish
EW Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $531.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.93%
12-Months-Change
Fundamentals
Return on Equity
15.71%
Trailing 12-Months
Asset Growth
33.56%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with better-than-expected sales growth and increased full-year guidance. Key product groups like TAVR and TMTT showed significant growth, and strategic approvals were secured. However, there were challenges related to manufacturing costs, foreign exchange impacts, and competitive pressures in certain markets.View all EW earnings summariesEW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
EW Stock 12 Month Forecast
Average Price Target
$88.64
▲(16.25% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
23.21% Mutual Funds
16.92% Other Institutional Investors
35.58% Public Companies and
Individual Investors